Your Health, We Care
Release date: 2024-08-09 10:55:58 Recommended: 149
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation.
EXKIVITY can cause cardiac toxicity (including decreased ejection fraction, cardiomyopathy, and congestive heart failure) resulting in heart failure which can be fatal. In the pooled EXKIVITY safety population, heart failure occurred in 2.7% of patients including 1.2% Grade 3 reactions, 0.4% Grade 4 reactions, and one (0.4%) fatal case of heart failure.
The clinical manifestatioEXKIVITY can cause clinical manifestations of cardiotoxicityns of cardiotoxicity are diverse, including the following:
Heart failure is one of the more severe manifestations of cardiotoxicity, and patients may experience symptoms such as dyspnea, shortness of breath, and edema, which is caused by the heart's weakened pumping function to meet the body's demand for blood and oxygen.
Cardiac toxicity may cause arrhythmias, including tachycardia, bradycardia, ventricular tachycardia, atrial fibrillation, etc., which can disrupt the normal rhythm of the heart and affect the heart's effective pumping function.
EXKIVITY (moboxantinib), as a targeted therapy drug, may cause a series of cardiotoxic reactions while treating cancers such as non-small cell lung cancer. The following measures should be taken to address these cardiotoxins:
Depending on the patient's specific condition and the severity of cardiotoxicity, the doctor may recommend adjusting the dose of EXKIVITY.
If patients experience severe cardiotoxicity during treatment, such as heart failure, significantly reduced ejection fraction or severe arrhythmias, the drug should be discontinued immediately and treated accordingly.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
